TY - JOUR
T1 - The Heterogeneity of Atopic Dermatitis
AU - Chovatiya, R.
AU - Silverberg, Jonathan I
PY - 2022/2/1
Y1 - 2022/2/1
N2 - BACKGROUND: Recent advances were made in characterizing the clinical heterogeneity of atopic dermatitis (AD). OBJECTIVE: To review the clinical domains contributing to AD heterogeneity and describe their importance in clinical practice. METHODS: We conducted a focused review of the published literature, including retrospective, observational, and prospective studies, clinical trials, and consensus guidelines. RESULTS: AD is associated with heterogeneous skin manifestations, symptoms, lesional severity, lesional extent, longitudinal course, burden of signs and symptoms, and comorbidities. Each of these domains characterizes a different aspect of AD and should be used to guide overall severity assessment and clinical management. Primary focus on any one specific clinical domain of AD is insufficient to describe the full burden of disease. CONCLUSION: Heterogeneity should be routinely considered during AD clinical encounters. J Drugs Dermatol. 2022;21(2):172-176. doi:10.36849/JDD.6408.
AB - BACKGROUND: Recent advances were made in characterizing the clinical heterogeneity of atopic dermatitis (AD). OBJECTIVE: To review the clinical domains contributing to AD heterogeneity and describe their importance in clinical practice. METHODS: We conducted a focused review of the published literature, including retrospective, observational, and prospective studies, clinical trials, and consensus guidelines. RESULTS: AD is associated with heterogeneous skin manifestations, symptoms, lesional severity, lesional extent, longitudinal course, burden of signs and symptoms, and comorbidities. Each of these domains characterizes a different aspect of AD and should be used to guide overall severity assessment and clinical management. Primary focus on any one specific clinical domain of AD is insufficient to describe the full burden of disease. CONCLUSION: Heterogeneity should be routinely considered during AD clinical encounters. J Drugs Dermatol. 2022;21(2):172-176. doi:10.36849/JDD.6408.
UR - http://www.scopus.com/inward/record.url?scp=85124257335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124257335&partnerID=8YFLogxK
U2 - 10.36849/JDD.6408
DO - 10.36849/JDD.6408
M3 - Review article
C2 - 35133102
AN - SCOPUS:85124257335
VL - 21
SP - 172
EP - 176
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
SN - 1545-9616
IS - 2
ER -